Abstract Details

Title Patient and Caregiver Perceptions of Acute Seizure Medications and the Rapid and Early Seizure Termination (REST) Approach: Qualitative Interviews

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P4 - Poster Session 4 (8:00 AM-9:00 AM)

Poster/Presentation
Number 11-003

Objective To assess understanding of the awareness of the Rapid and Early Seizure Termination (REST) paradigm and perceptions around acute (on-demand) medications among people with epilepsy (PwE) and caregivers.

Background REST is essential to prevent seizures becoming prolonged seizures (PS)/progressing in severity.

Design/Methods Participants included PwE (aged ≥18 years, with a diagnosis of epilepsy/an epilepsy syndrome and ≥1 PS [≥2 minutes] in prior 12 months) and caregivers (aged ≥18 years) of PwE (aged ≥12 years) from France/Italy/Poland/Spain/UK/US. They participated in 60-90-minute qualitative interviews regarding experiences with auras/epilepsy concepts/experience and unmet needs of acute medications/perceptions of REST. Interviews were recorded/analyzed using formal qualitative coding techniques.

Results 53 participants (18 PwE, 35 caregivers): 83% female and median (Q1, Q3) age 47 (40, 51) years. Of 44 participants who reported experiencing auras, 30 (68%) were extremely/very confident that they could predict a seizure from auras. The most frequent description of PS given was longer than 5 minutes (32%). Only 7 (13%) participants did not use/administer benzodiazepines (BZDs) as acute medication for PS. Regarding acute medication, 19 (36%) participants desired to change the mode of administration; 12 (23%) wanted improved effectiveness: “First and foremost, it should work effectively and stop the seizure very quickly.” 28 (53%) respondents perceived REST medication as quick/fast if it acts within the first minute of the seizure. 8 (15%) participants were aware of the REST concept. Of 45 participants not currently following the REST approach, 30 (67%) perceived REST to be feasible.

Conclusions Most participants reported they could confidently predict seizures based on auras, and few did not use/administer BZDs as acute medication for PS. Unmet needs of current acute medications were effectiveness and mode of administration. Most participants felt that REST is a feasible approach. REST could be a beneficial, fast-acting approach to prevent prolonged/more severe seizures.

Authors/Disclosures
Cedric Laloyaux, PhD (UCBMedical Affairs Center of Expertise) PRESENTER	Dr. Laloyaux has received personal compensation for serving as an employee of UCB.
Kerrie-Anne Ho (UCB)	Kerrie-Anne Ho has stock in Ucb.
Tommi Tervonen, PhD	Dr. Tervonen has nothing to disclose.
Jesus E. Pina-Garza, MD (Tristar Children's Specialists)	Dr. Pina-Garza has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Jazz. Dr. Pina-Garza has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis. Dr. Pina-Garza has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sk. Dr. Pina-Garza has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Pina-Garza has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Analysis Group/Acadia. Dr. Pina-Garza has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Same as consultant disclosure. Dr. Pina-Garza has received publishing royalties from a publication relating to health care.
Manuel Toledo	Manuel Toledo has nothing to disclose.
Sheryl R. Haut, MD (Albert Einstein College of Medicine)	Dr. Haut has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ventus. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbieVe. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Iqvia.
Tanya Bhatia, UCB Patient Author	Ms. Bhatia has nothing to disclose.
Aura Cecilia Jimenez-Moreno (Evidera)	Aura Cecilia Jimenez-Moreno has nothing to disclose.

��ɫ��

��ɫ��